Medicare payments aid Hologic results
Bone densitometry vendorHologic last week announced strong revenue and income growth forthe third quarter (end-June). The company's prospects have beenhelped by the Health Care Financing Administration's decisionto provide Medicare reimbursement for dual
Bone densitometry vendorHologic last week announced strong revenue and income growth forthe third quarter (end-June). The company's prospects have beenhelped by the Health Care Financing Administration's decisionto provide Medicare reimbursement for dual energy x-ray examinations(DXA) to measure bone density.
Hologic, of Waltham, MA, recorded third-quarter revenues of$10.9 million, up 65% from $6.6 million in the same quarter ayear ago. Hologic enjoyed net income of $1.2 million, comparedto a net loss of $169,000 in the third quarter of last year.
Hologic's sales were led by its QDR bone densitometers, inparticular QDR-2000plus, according to chairman and CEO David Ellenbogen.The system was introduced in September 1993.
In addition to Medicare reimbursement, Hologic has been helpedby a Japanese initiative to provide widespread osteoporosis screeningfor its citizens. Hologic has also seen sales grow in PacificRim and Latin American countries, the company said.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
